Thrombosis risk for TAFI antigen
| TAFI Antigen (U/dL) . | Patients n (%) . | Controls n (%) . | OR . | 95% CI . |
|---|---|---|---|---|
| < 96 | 94 (20) | 86 (18) | 1* | |
| 96-103 | 105 (22) | 98 (21) | 1 | 0.7-1.5 |
| 104-109 | 86 (18) | 94 (20) | 0.8 | 0.6-1.3 |
| 110-116 | 74 (16) | 96 (20) | 0.7 | 0.5-1.1 |
| > 116 | 115 (24) | 100 (21) | 1.1 | 0.7-1.6 |
| TAFI Antigen (U/dL) . | Patients n (%) . | Controls n (%) . | OR . | 95% CI . |
|---|---|---|---|---|
| < 96 | 94 (20) | 86 (18) | 1* | |
| 96-103 | 105 (22) | 98 (21) | 1 | 0.7-1.5 |
| 104-109 | 86 (18) | 94 (20) | 0.8 | 0.6-1.3 |
| 110-116 | 74 (16) | 96 (20) | 0.7 | 0.5-1.1 |
| > 116 | 115 (24) | 100 (21) | 1.1 | 0.7-1.6 |
Reference category.